Research and Publication Ethics

Written on 12 Nov 2014 / Recently revised on 30 Jun 2022
31 Dec 2022

All manuscripts should be written with strict adherence to the ethical guidelines recommended by the International Committee of Medical Journal Editors (http://www.icmje.org). Issues of ethical misconduct, plagiarism, and duplicate/redundant publication will be judged and dealt with according to the “Good Publication Practice Guidelines for Medical Journals” (https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13&per_page=). For all studies involving human subjects, the principles embodied in the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) should be upheld, informed consent must be obtained from all participants, and must be approved by a recognized Institutional Review Board (IRB) or research ethics committee. Experiments involving animals should comply with the NIH guidelines for the use of laboratory animals (https://olaw.nih.gov/) and/or be reviewed by an appropriate committee (Institutional Animal Care and Use Committee, IACUC) to ensure the ethical treatment of animals in research. The content of each article is responsible of the authors and not that of the Korean society for phlebology. For the policies on the research and publication ethics not stated in this instruction, International standards for editors and authors (https://publicationethics.org/resources/resources-and-further-reading/international-standards-editors-and-authors) can be applied.

1) Originality and duplicate publication

All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There will also be penalties for the authors. If the author(s) wishes to obtain a duplicate or secondary publication for various other reasons, such as for readers of a different language, he/she should obtain approval from the editors-in-chief of both the first and second journal.

2) Authorship

Those who made a substantial intellectual contribution in writing the manuscript should be included as an author. The authorship requires substantial contributions to (a) the conception and design or analysis and interpretation of the data, (b) the drafting of the article or critical revision for important intellectual content, (c) final approval of the version to be published, and (d) agreement accountable for all aspects of the work in ensuring the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The other contributions including providing funding or simple technical support should be mentioned in the Acknowledgment section. The primary investigator is designated the first author of the study, unless contested by the other authors. The corresponding author is directly responsible for communication with the journal during the manuscript submission, peer review, and publication process.

3) Conflicts of interest

All authors are required to report potential conflicts of interest that could inappropriately influence the author's work. This includes any financial or other relationships with commercial entities whose products or services are related to the subject matter in the manuscript, or sociopolitical issues that can cause conflict.

4) Registration of clinical trial research

Clinical trials should be registered with a primary national clinical trial registration site such as http://cris.nih.go.kr, or other sites accredited by the WHO or the International Committee of Medical Journal Editors (http://www.icmje.org), preferably prospectively, and the registration number, the registry name, and access details should be included in the paper.

5) Sex and gender equity in research

Ann Phlebology is particularly interested in experiments involving both male and female subjects studied at the same time, and the sufficient sample size to ensure meaningful statistical comparisons. Please ensure the correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors). Any paper utilizing subjects (cells, animals, and humans) of only one sex must state the sex of the samples in the paper, with the obvious exception of sex-specific issues (e.g., uterus or prostate). For cellular research, the sex of origin of cells used should be described. Authors must also state the rationale for using samples from one sex rather than from both. It is recommended for authors to follow the SAGER (Sex and Gender Equity in Research) guidelines (https://doi.org/10.1186/s41073-016-0007-6).

AP
Vol.21 No.2 Dec 31, 2023, pp. 53~101

Most Keyword ?

What is Most Keyword?

  • It is the most frequently used keyword in articles in this journal for the past two years.

Most Read

Annals of Phlebology